Skip to main content
    C

    Coherus BioSciences Inc (CHRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.48
    -0.03 (-5.42%)

    Market Cap: $81.21M

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Coherus BioSciences Inc (CHRS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Coherus BioSciences (CHRS) has a market cap of $81.21M and an enterprise value of $80.27M. It kept -253.43% of revenue as net income over the last 12 months. Its share count is up 33.33% from a year earlier.

    Total Valuation

    Enterprise value is 1.15% below the market cap, as cash exceeds debt.

    Market Cap$81.21M
    Enterprise Value$80.27M
    Latest price (Nov 17, 2026)$0.48

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.10% in the quarter ended Sep 30, 2026 and grew 15.98% a year over 2 years.

    Shares Outstanding154.97M
    Shares Change (YoY)+33.33%
    Shares Change (QoQ)+0.10%
    Share Count Growth (2Y CAGR)+15.98%

    Valuation Ratios

    Sales and book value multiples are 1.4x and 2.9x. Its year-end P/S ranged from 1.2x to 153.9x from 2016 to 2025.

    P/S Ratio1.4x
    Forward P/S1.4x
    P/B Ratio2.9x

    Valuation history and multiples

    Price Statistics

    The stock is down 59.79% over 52 weeks and trades 52.94% below its 50-day average.

    Beta (1Y)2.05
    52-Week Change-59.79%
    1-Month Change-50.09%
    3-Month Change-64.02%
    6-Month Change-67.67%
    5-Year Change-95.04%
    10-Year Change-96.96%
    Total Return (1Y)-59.79%
    Total Return (3Y CAGR)-39.20%
    Total Return (5Y CAGR)-51.89%
    Max Drawdown (1Y)-80.94%
    Max Drawdown (3Y)-85.63%
    Sharpe Ratio (1Y)-1.06
    Correlation with SPY (1Y)0.32
    50-Day Average$1.02
    200-Day Average$1.45
    52-Week Range$0.48 to $2.62
    RSI (14 Days)26.8
    Average Volume (20 Days)2.56M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.51x current liabilities, and total debt is 2.08x shareholder equity.

    Current Ratio1.51x
    Quick Ratio1.45x
    Debt / Equity2.08x
    Interest Coverage-11.05x

    Returns and Efficiency

    Return on invested capital is -144.80% and return on equity is -538.38% over the last 12 months.

    Return on Equity (ROE)-538.38%
    Return on Assets (ROA)-79.45%
    Return on Invested Capital (ROIC)-144.80%
    Return on Capital Employed (ROCE)-149.37%
    ROA (5Y Average)-13.87%
    Asset Turnover0.16x
    Inventory Turnover3.09x
    Receivables Turnover3.89x
    Cash Conversion Cycle-100 days

    Scores

    CHRS has an Altman Z-Score of -13.98, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-13.98
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $53.64M over the last 12 months is up 44.36% from the 12 months before.

    Revenue$53.64M
    Revenue Growth (YoY)+44.36%
    Gross Profit$37.45M
    Operating Income-$148.01M
    Pretax Income-$155.50M
    Net Income-$135.94M
    EBITDA-$139.11M
    EBIT-$142.60M
    Reported EPS (TTM)-$1.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 14.76% of the $171.10M in total assets.

    Cash and Equivalents$53.49M
    Total Debt$52.55M
    Net Cash$936.00K
    Net Cash Per Share$0.01
    Working Capital$38.49M
    Shareholder Equity$25.25M
    Book Value Per Share$0.16
    Tangible Book Value-$19.11M
    Total Assets$171.10M
    Total Liabilities$145.85M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$173.71M
    FCF Per Share-$1.12
    Depreciation and Amortization$3.49M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -275.94%.

    Gross Margin69.81%
    Operating Margin-275.94%
    Pretax Margin-289.91%
    Net Margin-253.43%
    EBITDA Margin-259.34%
    EBIT Margin-265.86%
    Gross Margin (5Y Average)64.30%
    Net Margin (5Y Average)37.56%

    Growth

    Revenue fell 41.54% a year over 3 years.

    Revenue Growth (3Y CAGR)-41.54%
    Revenue Growth (5Y CAGR)-38.41%

    Revenue and profit by year

    Dividends and Yields

    CHRS does not pay a dividend.

    Buyback Yield-83.49%
    Shareholder Yield-83.49%

    Peer Position

    Against 8 similar companies, CHRS has the 6th highest P/S.

    P/S Ratio1.4x vs 4.4x median
    ROIC-144.80% vs -8.39% median
    Revenue Growth (Trailing 4 Quarters, YoY)+44.36% vs +6.65% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 48.42% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+48.42%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CHRS

    What is CHRS's market cap?

    Coherus BioSciences has a market cap of $81.21M. Its enterprise value, which adds debt and subtracts cash, is $80.27M.

    How many shares of CHRS are outstanding?

    Coherus BioSciences has 154.97M shares outstanding. The count is up 33.33% from a year earlier.

    Does CHRS pay a dividend?

    No. Coherus BioSciences does not pay a dividend.

    How much debt does CHRS have?

    Coherus BioSciences has $52.55M of total debt and $53.49M of cash and equivalents, a net cash position of $936.00K.